




Correction to: Dose–response effects on HbA_{1c} and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Matthias Blüher¹ · Julio Rosenstock² · Josef Hoefler³ · Raymond Manuel⁴ · Anita M. Hennige⁵

Published online: 13 February 2024
© The Author(s) 2024

Correction: Diabetologia
<https://doi.org/10.1007/s00125-023-06053-9>

The graphical abstract (available at <https://doi.org/10.1007/s00125-023-06053-9>) included a typographical error (‘insulin-dependent insulin secretion’, rather than ‘glucose-dependent insulin secretion’). The online version has been corrected.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00125-023-06053-9>

✉ Matthias Blüher
matthias.blueher@medizin.uni-leipzig.de

✉ Anita M. Hennige
anita.hennige@boehringer-ingenheim.com

¹ Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München, University of Leipzig and University Hospital Leipzig, Leipzig, Germany

² Velocity Clinical Research, Medical City, Dallas, TX, USA

³ Staburo GmbH, Munich, Germany, on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany

⁴ Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA

⁵ Boehringer Ingelheim International GmbH, Biberach an der Riß, Germany